NuCana PLCNASDAQ:NCNA
- LAST PRICE1.2700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.2500/ 5
- Ask / Lots1.5700/ 1
- Open / Previous Close--- / 1.2700
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NCNA |
|---|---|---|
| 09:32 ET | 1513 | 1.28 |
| 09:33 ET | 3543 | 1.28 |
| 09:35 ET | 338 | 1.27 |
| 09:42 ET | 200 | 1.25 |
| 09:48 ET | 136 | 1.2651 |
| 09:51 ET | 8909 | 1.271 |
| 09:55 ET | 128 | 1.2891 |
| 10:00 ET | 1500 | 1.2893 |
| 10:06 ET | 100 | 1.273 |
| 10:08 ET | 100 | 1.28 |
| 10:09 ET | 916 | 1.27 |
| 10:11 ET | 1000 | 1.27 |
| 10:13 ET | 1025 | 1.27 |
| 10:18 ET | 157 | 1.27 |
| 10:22 ET | 100 | 1.27 |
| 10:29 ET | 1500 | 1.27 |
| 10:42 ET | 8000 | 1.27 |
| 10:45 ET | 5100 | 1.29 |
| 10:49 ET | 200 | 1.2896 |
| 10:51 ET | 300 | 1.285 |
| 10:54 ET | 1200 | 1.29 |
| 10:56 ET | 600 | 1.285 |
| 10:58 ET | 18765 | 1.271 |
| 11:03 ET | 100 | 1.28 |
| 11:09 ET | 4908 | 1.28 |
| 11:32 ET | 500 | 1.285 |
| 11:34 ET | 100 | 1.28 |
| 11:36 ET | 200 | 1.28 |
| 11:41 ET | 100 | 1.288 |
| 11:45 ET | 140 | 1.29 |
| 11:48 ET | 100 | 1.28 |
| 11:52 ET | 145 | 1.2744 |
| 11:54 ET | 400 | 1.2821 |
| 12:01 ET | 700 | 1.29 |
| 12:06 ET | 1220 | 1.28 |
| 12:08 ET | 300 | 1.28 |
| 12:14 ET | 350 | 1.2797 |
| 12:39 ET | 100 | 1.28 |
| 12:44 ET | 100 | 1.2887 |
| 12:46 ET | 200 | 1.2899 |
| 12:48 ET | 1000 | 1.2891 |
| 01:00 ET | 864 | 1.28 |
| 01:02 ET | 100 | 1.275 |
| 01:24 ET | 1000 | 1.2713 |
| 01:26 ET | 150 | 1.2723 |
| 01:27 ET | 1300 | 1.28 |
| 01:33 ET | 200 | 1.28 |
| 01:44 ET | 320 | 1.28 |
| 01:51 ET | 1000 | 1.275 |
| 01:58 ET | 100 | 1.275 |
| 02:03 ET | 1200 | 1.2792 |
| 02:05 ET | 1000 | 1.28 |
| 02:21 ET | 2500 | 1.275 |
| 02:23 ET | 4600 | 1.279345 |
| 02:25 ET | 2600 | 1.275 |
| 02:34 ET | 500 | 1.2707 |
| 02:36 ET | 1000 | 1.2706 |
| 02:45 ET | 600 | 1.27 |
| 02:50 ET | 100 | 1.2785 |
| 02:52 ET | 100 | 1.275 |
| 02:57 ET | 100 | 1.28 |
| 03:10 ET | 1479 | 1.27 |
| 03:26 ET | 3000 | 1.279 |
| 03:32 ET | 400 | 1.27 |
| 03:33 ET | 383 | 1.27 |
| 03:35 ET | 100 | 1.28 |
| 03:42 ET | 150 | 1.2736 |
| 03:44 ET | 210 | 1.275 |
| 03:57 ET | 1900 | 1.275 |
| 04:00 ET | 1759 | 1.27 |
Nov 11, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NuCana PLC | 2.9M | 0.0x | --- |
Dogwood Therapeutics Inc | 3.6M | -0.5x | --- |
CTT Pharmaceutical Holdings Inc | 3.6M | -0.8x | --- |
Artelo Biosciences Inc | 3.6M | -0.4x | --- |
Channel Therapeutics Corp | 3.6M | -0.4x | --- |
Enzolytics Inc | 3.5M | 0.0x | --- |
Company Information
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Contact Information
- Headquarters
- Lochside House, 3 Lochside WayEDINBURGH, United Kingdom EH12 9DT
- Phone
- 131-248-3660
- Fax
- 131-248-3001
Executives
- Non-Executive Independent Chairman of the Board
- Andrew Kay
- Chief Executive Officer, Co-Founder, Executive Director
- Hugh Griffith
- Chief Financial Officer
- Donald Munoz
- Chief Medical Officer
- Jeffrey Bloss
- Head - Translational Studies
- David Harrison
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 90.7K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.97 |
EPS | $-221.84 |
Book Value | $8.86 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
